l-carnitina hipertenso pode tomar L-Carnitina: Para que serve? Como tomar? L Carnitina Liquida

In the News Antibody-drug conjugate achieves high response rates as frontline treatment in aggressive, rare blood cancer Leukemia specialists: How advances in measurable residual disease (MRD) are improving cancer care ASCO: New antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer ASH: Novel combination therapy significantly reduces spleen volume in patients with myelofibrosis Understanding the types of leukemia Reflections on caring for cancer patients during the COVID-19 pandemic New blastic plasmacytoid dendritic cell neoplasm (BPDCN) treatment improves outlook for many patients ARCHIVED: Investigational drug shows promising results in Phase II study of aggressive, often fatal blood disorder with no approved therapies Present Title & Affiliation Primary Appointment Professor, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX Dual/Joint/Adjunct Appointment Professor, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX Research Interests Patients with AML and BPDCN: CD123-targeted clinical trial with SL-401

-Amyloid-Associated Free Radical Oxidative Stress and Neurotoxicity: Implications for Alzheimer's Disease

BPC-157 can induce nitric oxide generation and activate eNOS (endothelial nitric oxide synthase), which is associated with tissue repair

Neuroprotection: extrapolating from neurologic disease to the eye